Mirae Asset Global Investments
PACB icon

Mirae Asset Global Investments’s Pacific Biosciences PACB Stock Holding History

Mirae Asset Global Investments’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3K Sell
13,891
-1,861
-12% -$2.71K ﹤0.01% 1469
2026
Q1 		$20.8K Buy
15,752
+1,081
+7% +$1.93K ﹤0.01% 1428
2025
Q4 		$27.4K Buy
14,671
+3,059
+26% +$5.88K ﹤0.01% 1499
2025
Q3 		$14.9K Buy
11,612
+20
+0.2% +$27 ﹤0.01% 1532
2025
Q2 		$14.4K Buy
11,592
+2,355
+25% +$2.72K ﹤0.01% 1442
2025
Q1 		$10.5K Buy
9,237
+111
+1% +$170 ﹤0.01% 1466
2024
Q4 		$17K Sell
9,126
-731
-7% -$1.43K ﹤0.01% 1443
2024
Q3 		$17.3K Buy
9,857
+1,726
+21% +$2.84K ﹤0.01% 1453
2024
Q2 		$11.1K Sell
8,131
-1,327,731
-99% -$2.68M ﹤0.01% 1454
2024
Q1 		$12.2M Buy
1,335,862
+408,874
+44% +$2.39M 0.03% 555
2023
Q4 		$9.09M Sell
926,988
-507,572
-35% -$4.15M 0.02% 686
2023
Q3 		$12M Buy
1,434,560
+41,970
+3% +$480K 0.03% 554
2023
Q2 		$18.5M Buy
1,392,590
+30,767
+2% +$374K 0.04% 442
2023
Q1 		$15.8M Buy
1,361,823
+400
+0% +$3.98K 0.04% 463
2022
Q4 		$11.1M Buy
1,361,423
+205,809
+18% +$1.77M 0.03% 563
2022
Q3 		$6.71M Buy
1,155,614
+176,087
+18% +$1.01M 0.02% 707
2022
Q2 		$4.33M Buy
979,527
+602,257
+160% +$3.66M 0.01% 886
2022
Q1 		$3.43M Sell
377,270
-68,930
-15% -$794K 0.01% 993
2021
Q4 		$9.13M Buy
446,200
+95,609
+27% +$2.31M 0.02% 707
2021
Q3 		$8.96M Buy
350,591
+69,263
+25% +$2.05M 0.02% 685
2021
Q2 		$9.84M Sell
281,328
-85,483
-23% -$2.49M 0.03% 639
2021
Q1 		$12.2M Buy
366,811
+165,541
+82% +$5.79M 0.04% 481
2020
Q4 		$5.22M Buy
201,270
+69,947
+53% +$1.19M 0.02% 645
2020
Q3 		$1.3M Buy
131,323
+41,588
+46% +$239K 0.01% 889
2020
Q2 		$309K Buy
89,735
+31,933
+55% +$109K ﹤0.01% 1291
2020
Q1 		$176K Buy
57,802
+6,292
+12% +$25.8K ﹤0.01% 1339
2019
Q4 		$265K Buy
51,510
+5,416
+12% +$27.5K ﹤0.01% 1373
2019
Q3 		$238K Buy
46,094
+32,713
+244% +$183K ﹤0.01% 1353
2019
Q2 		$81K Buy
+13,381
New +$93.8K ﹤0.01% 1383

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
BLAM
Bourne Lent Asset Management Pawling, New York $289M AUM 30.86% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAM
Carret Asset Management New York $1.14B AUM 35.33% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Mirae Asset Global Investments's PACB Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Pacific Biosciences (PACB) stake by 12% in Q2 2026, selling an estimated $2.71K and leaving 13,891 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1469.

Mirae Asset Global Investments first reported a position in PACB in Q2 2019 and has held it in 29 quarters since. The position peaked at $18.5M in Q2 2023. 81 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Mirae Asset Global Investments held 13,891 shares of Pacific Biosciences worth $23.3K as of Q2 2026.
  • Mirae Asset Global Investments sold 1,861 Pacific Biosciences shares in Q2 2026, an estimated $2.71K.
  • Pacific Biosciences made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1469 holding.
  • Mirae Asset Global Investments first reported a position in Pacific Biosciences in Q2 2019 and has held it in 29 quarters since.
  • Mirae Asset Global Investments's Pacific Biosciences position peaked at $18.5M in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.